A61K 47/6869
The tumour determinant being from a cell of the reproductive system: ovaria
Official title: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
A61K47/6869 (The tumour determinant being from a cell of the reproductive system: ovaria) appears on 405 US grants and 679 published applications in this corpus.
Search patents in A61K- Granted patents
- 405
- Published applications
- 679
- Assignees
- 241
- Inventors
- 1,197
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 3 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 4 | 0 |
| 2001 | 1 | 2 |
| 2002 | 1 | 7 |
| 2003 | 4 | 9 |
| 2004 | 5 | 9 |
| 2005 | 4 | 8 |
| 2006 | 4 | 11 |
| 2007 | 3 | 7 |
| 2008 | 5 | 11 |
| 2009 | 8 | 22 |
| 2010 | 7 | 8 |
| 2011 | 2 | 18 |
| 2012 | 15 | 22 |
| 2013 | 12 | 17 |
| 2014 | 19 | 44 |
| 2015 | 26 | 31 |
| 2016 | 33 | 54 |
| 2017 | 30 | 52 |
| 2018 | 31 | 41 |
| 2019 | 21 | 45 |
| 2020 | 30 | 38 |
| 2021 | 29 | 41 |
| 2022 | 28 | 33 |
| 2023 | 18 | 40 |
| 2024 | 23 | 36 |
| 2025 | 20 | 47 |
| 2026 | 14 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Monoclonal antibody used for diagnosis and early onset of prostate cancer6 Oct 2026US 12,753,244 B2Taipei Medical University
- Proteins that bind SP17 including fully-human anti-SP17 antibodies9 Jun 2026US 12,649,790 B2Medicovestor, Inc.
- Radiohalogen prosthetic moieties and radiolabeled biomolecules26 May 2026US 12,637,398 B2Duke University
- Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins12 May 2026US 12,624,097 B2Medicovestor, Inc.
- Photosensitizing antibody-fluorophore conjugates5 May 2026US 12,616,751 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Anti-psma antibodies and uses thereof8 Oct 2026US 2026/0308273 A1Bristol-Myers Squibb Company
- Multifunctional antibodies10 Sep 2026US 2026/0263645 A1Telix Pharmaceuticals (Innovations) Pty Ltd.
- Crosslinking antibodies10 Sep 2026US 2026/0263646 A1Enlaza Therapeutics, Inc.
- Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy27 Aug 2026US 2026/0248948 A1Imperial College Innovations Limited
- Anti-psma antibodies, conjugates, and methods of use20 Aug 2026US 2026/0241024 A1Eisai R&D Management Co., Ltd.
Most cited
By later US patents
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Camptothecin-binding moiety conjugates76US 8,268,317 B2Immunomedics, Inc. · 2012
- Methods of treating acute myeloid leukemia by blocking CD4775US 8,562,997 B2The Board of Trustees of the Leland Stanford Junior University · 2013
- Antibodies specific for Trop-2 and their uses72US 8,871,908 B2Rinat Neuroscience Corp. · 2014
- Treatment and diagnosis of cancer70US 7,163,680 B2Cornell Research Foundation, Inc. · 2007